Abstract: Silencing of Influenza virus RNA can be achieved by siDNA. These are oligodeoxynucleotides having an antisense-strand homologous to the viral RNA and a second strand, partially complementary to the antisense-strand. The two strands are preferentially linked by a linker (eg 4 thymidines). Triple-helix formation with the target RNA is a preferred effect. The siDNA is superior to siRNA because it acts earlier, is easier taken up by the cell, the formation of RNA-DNA hybrids is preferred over double-stranded DNA or double-stranded RNA, which forms as tertiary structures in RNA genomes. Also the induction of interferon is less likely. siDNA is easier to synthesize and it is more stable. It can be combined with siRNA.

Abstract: Described is the use of a nucleic acid molecule encoding an IL-12 polypeptide for the preparation of a pharmaceutical composition for the treatment of a tumor, wherein the pharmaceutical composition is for intra-tumoral administration.

Abstract: Disclosed are nucleic acid molecules encoding a protein interacting with the Ser/Thr kinase Akt as well as the encoded protein. Furthermore, the invention describes expression vectors, host cells, antibodies, pharmaceutical compositions and methods for treating disorders associated with impaired endosomal transport.

Abstract: Described is the use of a nucleic acid molecule encoding an IL-12 polypeptide for the preparation of a pharmaceutical composition for the treatment of a tumor, wherein the pharmaceutical composition is for intra-tumoral administration.

Abstract: The present invention relates to a pharmaceutical or vaccine composition comprising a nucleic acid molecule encoding a tumor-associated antigen and at least one peptide comprising a region corresponding to a putative cytotoxic T cell, helper T cell or B cell epitope of a tumor-associated antigen and/or cells pulsed with such peptides, optionally in combination with a pharmaceutically acceptable carrier. Such pharmaceutical compositions can be used for the treatment of cancer or for the vaccination against cancer.

Abstract: Disclosed is a nucleic acid molecule encoding a protein interacting with the carboxy terminus of the chemokine receptor CCR5 or of other chemokine receptor family members as well as the encoded protein. Furthermore, the invention describes expression vectors, host cells, antibodies, antagonists, pharmaceutical compositions and methods for treating HIV infection and progression to AIDS.

Abstract: The subject matter of the invention is the use of organic polymers which contain inorganic anionic groups for prophylaxis and therapy of retrovirus infections in mammals.

Abstract: A rapidly cleavable substrate for HIV protease Hepta- to nona-peptides of the formulaA--B--C--D--E--Opr--F--G--H,in which A is absent or represents Val, Ile or Thr, B denotes Ser, Thr or Phe, D denotes Asp or Ala, E denotes Tyr or Phe, Opr denotes 5-oxaproline, F denotes Ile, Leu, Val, Thr or Gln, G denotes Val, Ile, Ser or Arg, and H is absent or represents Gln, Glu, Pro or Thr, as well as the salts thereof are used for locating and detecting HIV protease and for testing possible inhibitors of HIV protease. They are prepared by known methods of peptide chemistry, preferably by means of solid-phase synthesis.